Patents by Inventor Kevin Michael Foote

Kevin Michael Foote has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds
    Patent number: 10301267
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: May 28, 2019
    Assignee: AstraZeneca AB
    Inventors: David Buttar, Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas
  • NOVEL COMPOUNDS
    Publication number: 20170260143
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Inventors: David BUTTAR, Kevin Michael FOOTE, Maria-Elena THEOCLITOU, Andrew Peter THOMAS
  • Methods of treating cancer with a pyrazole derivative
    Patent number: 9688640
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: June 27, 2017
    Assignee: ASTRAZENECA AB
    Inventors: David Buttar, Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas
  • Chemical compounds
    Patent number: 9421213
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: August 23, 2016
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink, Paul Turner
  • Chemical Compounds
    Publication number: 20160074412
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: September 21, 2015
    Publication date: March 17, 2016
    Applicant: AstraZeneca AB
    Inventors: Kevin Michael Foote, Johannes Wilhelmus, Maria Nissink, Paul Turner
  • NOVEL COMPOUNDS
    Publication number: 20150299134
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Application
    Filed: June 26, 2015
    Publication date: October 22, 2015
    Applicant: AstraZeneca AB
    Inventors: David BUTTAR, Kevin Michael FOOTE, Maria-Elena THEOCLITOU, Andrew Peter THOMAS
  • Chemical compounds
    Patent number: 9155742
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: October 13, 2015
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink, Paul Turner
  • Chemical Compounds
    Publication number: 20150164908
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: February 26, 2015
    Publication date: June 18, 2015
    Applicant: AstraZeneca AB
    Inventors: Kevin Michael Foote, Johannes Wilhelmus, Maria Nissink, Paul Turner
  • NOVEL COMPOUNDS
    Publication number: 20140066455
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Application
    Filed: November 13, 2013
    Publication date: March 6, 2014
    Applicant: AstraZeneca AB
    Inventors: David BUTTAR, Kevin Michael FOOTE, Maria-Elena THEOCLITOU, Andrew Peter THOMAS
  • N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof
    Patent number: 8604022
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: December 10, 2013
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas, David Buttar
  • Pyridine compounds
    Patent number: 8569298
    Abstract: The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: October 29, 2013
    Assignee: Astrazeneca AB
    Inventors: Bernard Christophe Barlaam, Patrick Ple, Kevin Michael Foote, Clifford David Jones
  • Chemical compounds
    Patent number: 8552004
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: July 2, 2012
    Date of Patent: October 8, 2013
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Paul Turner, Johannes Wilhelmus Maria Nissink
  • CHEMICAL COMPOUNDS
    Publication number: 20130005725
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: July 2, 2012
    Publication date: January 3, 2013
    Applicant: AstraZeneca AB
    Inventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink, Paul Turner
  • Chemical compounds
    Patent number: 8252802
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: August 28, 2012
    Assignee: Astrazeneca AB
    Inventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink, Paul Turner
  • N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF
    Publication number: 20120129844
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Application
    Filed: January 26, 2012
    Publication date: May 24, 2012
    Inventors: David Buttar, Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas
  • N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof
    Patent number: 8129391
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: March 6, 2012
    Assignee: AstraZeneca AB
    Inventors: Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas, David Buttar
  • CHEMICAL COMPOUNDS
    Publication number: 20110306613
    Abstract: There is provided pyrimidinyl compounds of Formula (I), wherein: R2 is or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: June 9, 2011
    Publication date: December 15, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink, Paul Turner
  • PYRIDINE COMPOUNDS
    Publication number: 20110166139
    Abstract: The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.
    Type: Application
    Filed: June 15, 2009
    Publication date: July 7, 2011
    Applicant: ASTRAZENECA AB
    Inventors: Bernard Christophe Barlaam, Patrick Ple, Kevin Michael Foote, Clifford David Jones
  • CHEMICAL COMPOUNDS 610
    Publication number: 20110053923
    Abstract: There is provided pyrimidinyl indole compounds of Formula (I), or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 21, 2009
    Publication date: March 3, 2011
    Applicant: AstraZeneca
    Inventors: Kevin Michael Foote, Johannes Wilhelmus Maria Nissink
  • N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof
    Publication number: 20100273811
    Abstract: There is provided a compound of formula (I): or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
    Type: Application
    Filed: April 30, 2010
    Publication date: October 28, 2010
    Inventors: David Buttar, Kevin Michael Foote, Maria-Elena Theoclitou, Andrew Peter Thomas